BROADWOOD PARTNERS, L.P. (Bradsher Neal C) purchased $6.0M of IMDX

BROADWOOD PARTNERS, L.P. purchased 3,428,571 shares of Insight Molecular Diagnostics Inc. (IMDX) at $1.75 ($6.00M total) on 2026-11-17. Filed jointly with BROADWOOD CAPITAL INC (10% owner) and Bradsher Neal C (10% owner).

Original reporting
SEC EDGAR · BROADWOOD PARTNERS, L.P., BROADWOOD CAPITAL INC, Bradsher Neal C
Published Nov 19, 2026, 10:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 11:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IMDX
Bullish
medium confidence
Mentioned
$IMDX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMDXBullishLow
01

Why it matters

The disclosed open-market purchase by a 10% owner may modestly influence trading sentiment, but it does not introduce new operational or financial information.

02

Market read

Traders may treat the transaction as a small bullish signal for IMDX, but with low decision urgency absent new guidance or results.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it also provides no rationale for the buy, no follow-on guidance, and no confirmation of sustained buying beyond this single transaction.

Relevance 7/10Novelty 6/10Timing: SEC Form 4 filed Nov. 19, covering a purchase on Nov. 17

Background

The article is an SEC Form 4 insider transaction disclosure for Insight Molecular Diagnostics (IMDX).

Company-level read

Ticker impact

$IMDXBullishMedium confidence
Context

Broadwood Partners, a 10% owner, bought 3,428,571 shares of Insight Molecular Diagnostics at $1.75/share in an SEC Form 4 filed Nov. 19.

Expected impact

Likely mild support or reduced downside as the market interprets the purchase as bullish, though impact should be limited because it is an insider transaction rather than new company guidance.

Evidence & confidence

Form 4 insider purchases can influence sentiment, but the article provides no new business, financial, or regulatory catalyst beyond the transaction details.

Market effects

Limited sector read-through; this is a single-company ownership transaction with no stated industry-wide catalyst.

None indicated.

None indicated.

Counterpoint

A large-holder purchase can be driven by liquidity needs, diversification, or pre-arranged plans not reflected here, so it may not reflect near-term fundamentals.

Key entities

  • Insight Molecular Diagnostics Inc.

    Company whose shares were purchased; subject of the Form 4 insider transaction.

  • Broadwood Partners, L.P.

    10% owner that reported the open-market purchase.

  • Bradsher Neal C

    10% owner co-reporting the transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IMDXMed

IMDx Reports Third Quarter 2026 Results and Provides Corporate Update

Insight Molecular Diagnostics Inc. (IMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMDx Reports Third Quarter 2026 Results and Provides Corporate Update ● Progress with FDA review of GraftAssureDx and its planned response to FDA’s request for additional information ● Initiated enrollment into GALACTIC registry study from UCLA Medical Center ● Reven

$IMDXMed

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

Insight Molecular Diagnostics Inc. (IMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx ● Discussions with FDA advance toward expected marketing authorization for GraftAssureDx ● FDA completes current portion of substantive review in a timely manner ● Favorable M